Williams, A. K., Klein, M. D., Martin, J., Weck, K. E., Rossi, J. S., Stouffer, G. A., & Lee, C. R. (2019). CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. Circulation. Genomic and Precision Medicine, 12(2), e002441. https://doi.org/10.1161/circgen.119.002441

Williams, Alexis K., Melissa D. Klein, Jesse Martin, Karen E. Weck, Joseph S. Rossi, George A. Stouffer, and Craig R. Lee. “CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.” Circulation. Genomic and Precision Medicine 12, no. 2 (February 2019): e002441. https://doi.org/10.1161/circgen.119.002441.

Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, et al. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. Circulation Genomic and precision medicine. 2019 Feb;12(2):e002441.

Williams, Alexis K., et al. “CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.” Circulation. Genomic and Precision Medicine, vol. 12, no. 2, Feb. 2019, p. e002441. Epmc, doi:10.1161/circgen.119.002441.

Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, Lee CR. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. Circulation Genomic and precision medicine. 2019 Feb;12(2):e002441.